• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    STRATA Skin Sciences Appoints William D. Humphries to Its Board of Directors

    4/12/21 4:05:00 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care
    Get the next $SSKN alert in real time by email

    HORSHAM, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of William D. Humphries to its Board of Directors.

    Mr. Humphries' vast experience includes more than 34 years as a key leader in the pharmaceutical industry, contributing strategic direction to a range of high growth public and privately-owned companies.

    "We are delighted to welcome Bill to STRATA Skin Science's board," said Uri Geiger, Chairman of STRATA's Board of Directors. "His extensive background in the pharmaceutical industry will provide invaluable leadership as the Company seeks to expand its role in the dermatologic space."

    From August 2018 until December 2020, Mr. Humphries served as President and Group Company Chairman, Ortho Dermatologics of Bausch Health Companies Inc., where he previously served as Executive Vice President, Company Group Chairman, Dermatology from January 2017 to August 2018. From 2012 to December 2016, he served as President and Chief Executive Officer of the North American business of Merz, Inc., an affiliate of Merz Pharma Group, a specialty healthcare company. From 2004 to 2012, he served in several leadership positions with Stiefel Laboratories, Inc., a dermatology pharmaceutical company, including as its Chief Commercial Officer and then as its President beginning in 2008. Stiefel was acquired by GlaxoSmithKline in 2009. After the acquisition, Mr. Humphries served as the President of Dermatology for Stiefel, a GSK Company from 2009 until 2012. Before Stiefel, Mr. Humphries served in executive roles in sales and marketing, business development, and international marketing for Allergan, Inc., concluding as vice president of its U.S. skincare business.

    "STRATA Skin Sciences has long been at the forefront of the treatment of dermatologic conditions and I am excited to join such an impressive team," said Mr. Humphries. "My background aligns very well with the Company's mission and I look forward to advising on future innovation."

    Mr. Humphries currently serves as Chairman of the Board at Clearside Biomedical, Chairman of the North Carolina State University Global Luxury Management Board and is a member of the Board at Aclaris Therapeutics. He received his MBA from Pepperdine University and completed his undergraduate studies at Bucknell University.

    About STRATA Skin Sciences, Inc. 

    STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.

    The Company's proprietary XTRAC excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents.

    STRATA's unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company's partner dermatology clinics.

    Investor Contact

    Leigh Salvo
    (415) 937-5404
    [email protected]


    Primary Logo

    Get the next $SSKN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SSKN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SSKN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases

      HORSHAM, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to advancing dermatologic care through innovation, announces that the American Medical Association (AMA) CPT Editorial Panel, in its May, 2025 summary of panel actions (May 2025: CPT® Editorial Summary of Panel Actions | AMA) has accepted revision to CPT codes 96920-96922, expanding reimbursement eligibility for excimer laser treatments to include multiple inflammatory and auto-immune skin conditions beyond their original psoriasis indication. This change reflects over 20 years of clinical evidence and real-world use of STRATA's XTRAC®

      5/19/25 8:00:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update. First Quarter 2025 Financial Highlights Revenue in the first quarter of 2025 was $6.8 million, up 1% Global net recurring XTRAC® revenue in the first quarter was $4.5 million vs. $4.6 million in the prior year period, with international growth of 27% offsetting a 4% decline in the domestic marketAverage net revenue per dome

      5/14/25 4:05:00 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference

      HORSHAM, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will participate in the D. Boral Capital Inaugural Global Conference. The conference is being held on May 14, 2025, at The Plaza Hotel, 768 Fifth Avenue, New York, NY 10019. President and Chief Executive Officer Dr. Dolev Rafaeli will be hosting one-on-one meetings on May 14, 2025 from 9:00 AM to 3:00 PM (ET). To register for one-on-one meetings with management at The Plaza Hotel in New York City, intereste

      5/8/25 8:15:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Strata Skin Sciences Inc.

      SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

      11/14/24 2:04:43 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Strata Skin Sciences Inc.

      SC 13D/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

      7/18/24 7:42:09 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Strata Skin Sciences Inc. (Amendment)

      SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

      2/14/24 4:51:41 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Geiger Uri bought $723,999 worth of shares (230,573 units at $3.14) (SEC Form 4)

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      7/17/24 5:08:57 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Large owner Accelmed Partners, L.P. bought $723,999 worth of shares (230,573 units at $3.14), increasing direct ownership by 19% to 1,441,835 units (SEC Form 4)

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      7/17/24 5:08:11 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Rafaeli Dolev bought $59,974 worth of shares (19,100 units at $3.14), increasing direct ownership by 15% to 143,156 units (SEC Form 4)

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      7/17/24 5:01:09 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Financials

    Live finance-specific insights

    See more
    • STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update. First Quarter 2025 Financial Highlights Revenue in the first quarter of 2025 was $6.8 million, up 1% Global net recurring XTRAC® revenue in the first quarter was $4.5 million vs. $4.6 million in the prior year period, with international growth of 27% offsetting a 4% decline in the domestic marketAverage net revenue per dome

      5/14/25 4:05:00 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Report First Quarter 2025 Financial Results on May 14, 2025 and Provide Corporate Update

      HORSHAM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2025 financial results on Wednesday, May 14, 2025 after the market close. STRATA management will subsequently host a conference call at 5:00 p.m. ET on Wednesday, May 14, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interested pa

      5/7/25 8:15:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update

      HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report fourth quarter and year end 2024 financial results on Thursday, March 27, 2025 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Thursday, March 27, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interest

      3/21/25 1:43:43 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    SEC Filings

    See more
    • Strata Skin Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)

      5/14/25 5:25:17 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by Strata Skin Sciences Inc.

      10-K/A - STRATA Skin Sciences, Inc. (0001051514) (Filer)

      4/30/25 4:33:20 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Strata Skin Sciences Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)

      4/25/25 4:30:45 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Gov Shmuel

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:21:12 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Accounting Officer Gillings John T

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:14:28 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Rafaeli Dolev

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:09:40 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Leadership Updates

    Live Leadership Updates

    See more
    • Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

      Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

      11/28/23 8:30:00 AM ET
      $APYX
      $PDSB
      $SSKN
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • STRATA Skin Sciences Appoints Dr. Uri Geiger to Chairman of its Board of Directors

      HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation. "I'm honored to assume the role of Chairman at this pivotal moment in STRATA's growth," said Dr. Uri Geiger, Chairman of STRATA's Board of Directors. "I look forward to levera

      6/30/23 8:00:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences Appoints Patricia S. Walker, M.D., Ph.D. to its Board of Directors

      HORSHAM, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors. Dr. Walker's vast experience includes more than 35 years as a practicing dermatologist and as a corporate leader in the medical dermatology, medical aesthetics and pharmaceutical industries, executing clinical research and strategic initiatives for a wide range of companies and educational institutions. "We are delighted to welcome Patty to STRAT

      2/14/22 4:05:00 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care